Recent Milestones: Lead Optimization, Translational Studies

Upcoming Milestones: Candidate Selection / IND-enabling Studies

Products: Selective small molecule CaV2.3 Inhibitors as precision medicines for the treatment of neurological disorders

Investors: Epidarex Capital, Golgi Neurosciences

Full Company address & contact details: Lario Therapeutics Ltd, 137A George Street, Edinburgh, EH2 4JY, UK Contact: henning@lariotx.com